Data beget progress.Such is the promise and hope of artificial intelligence, particularly machine learning, to match lung cancer patients with their optimal treatments.In this episode, Dr. Andrea Mazzocchi, Co-founder and CEO of Known Medicine, dissects the art and the science of how profiling biomarkers, epigenetics and the microenvironment may provide the synergy needed to revolutionize the oncologic landscape.